The Biotechnology Innovation Organization (BIO) has released the largest ever study of clinical development success rates, with a focus on the advantages of using biomarkers in clinical trials.
Some of the conclusions:
Clinical trial programs that used selection biomarkers saw an overall likelihood of approval (LOA) from Phase I of 25.9%, compared to 8.4% when no selection biomarkers were used.
Oncology drugs were approved the fastest of all 14 disease areas.
Read the study: http://bit.ly/22o5TGf